Greg DeFilippis

Chief Business Officer

Mr. DeFilippis brings to Halozyme almost 20 years of diversified leadership experience in pharmaceutical and medical device business development including roles in combination product development, device innovation, technical operations, commercial operations and alliance management. Mr. DeFilippis joined Halozyme in 2022 following the acquisition of Antares Pharma, Inc. where he held executive leadership roles as Senior Vice President, Device Business and Alliances from Vice President, Business Development and Alliances and Senior Director, Business Alliances and Device Supply Chain Management.

Prior to Halozyme, Mr. DeFilippis served as Director of Business Development for Teva Pharmaceuticals and held roles of increasing responsibility in technical operations, supply chain and continuous improvement at Barr Laboratories, Inc., Pliva, Inc., Actavis, Inc. and Alpharma, Inc.

Mr. DeFilippis holds a B.S. in Industrial and Systems Engineering from Virginia Tech, an M.B.A. in Finance from Fairleigh Dickinson and is a Lean Six Sigma Master Black Belt.